1. Home
  2. LUV vs INCY Comparison

LUV vs INCY Comparison

Compare LUV & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southwest Airlines Company

LUV

Southwest Airlines Company

HOLD

Current Price

$38.92

Market Cap

18.9B

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$113.38

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUV
INCY
Founded
1967
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9B
17.0B
IPO Year
1995
1994

Fundamental Metrics

Financial Performance
Metric
LUV
INCY
Price
$38.92
$113.38
Analyst Decision
Buy
Buy
Analyst Count
25
28
Target Price
$49.18
★ $129.50
AVG Volume (30 Days)
★ 5.1M
1.6M
Earning Date
10-21-2026
10-29-2026
Dividend Yield
★ 1.82%
N/A
EPS Growth
3.95
★ 4173.33
EPS
0.92
★ 1.47
Revenue
N/A
★ $3,394,635,000.00
Revenue This Year
$18.37
$15.52
Revenue Next Year
$5.19
$5.16
P/E Ratio
★ $42.94
$76.94
Revenue Growth
N/A
★ 13.67
52 Week Low
$29.26
$84.02
52 Week High
$55.11
$132.60

Technical Indicators

Market Signals
Indicator
LUV
INCY
Relative Strength Index (RSI) 40.12 40.83
Support Level $37.44 $110.56
Resistance Level $42.03 $119.29
Average True Range (ATR) 1.04 3.06
MACD -0.26 -0.14
Stochastic Oscillator 2.83 35.97

Price Performance

Historical Comparison
LUV
INCY

About LUV Southwest Airlines Company

Southwest Airlines is the largest domestic air carrier in the United States by passengers boarded. Southwest operates nearly 800 aircraft in an all-Boeing 737 fleet. Despite offering some longer routes and a few perks for business travelers, the airline predominantly specializes in short-haul, leisure flights operated with a simple cabin configuration in a point-to-point network. In early 2026, Southwest modified its cabins to offer some rows with extra legroom, its ticketing process and merchandising to offer assigned seats, and more fare categories to include a basic economy class that appears for the first time in travel aggregators' search results and more directly competes with other airlines' offerings.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: